Japanese firm Otsuka Pharmaceutical has agreed to acquire Avanir Pharmaceuticals, the California-based company that sells a reformulated cough and heart medicine combination to treat uncontrolled laughing and crying, for $3.5bn.
Otsuka coughs up $3.5bn for Avanir
Japanese firm Otsuka Pharmaceutical has agreed to acquire Avanir Pharmaceuticals, the California-based company that sells a reformulated cough and heart medicine combination to treat uncontrolled laughing and crying, for $3.5bn.
More from Neurological
More from Therapy Areas
• By
Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.
• By
The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.
• By
The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.